The past 30 years have seen rapid progress in classical APL treatment by using all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) to target the PML::RARA fusion protein, converting the disease from highly lethal to highly curable (7, 8). Here, RARA is linked to acute promyelocytic leukemia.